| Antituberculosis drug‐induced hepatotoxicity: concise up‐to‐date review A Tostmann, MJ Boeree, RE Aarnoutse, WCM De Lange, ... Journal of gastroenterology and hepatology 23 (2), 192-202, 2008 | 1031 | 2008 |
| The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study W Hoefsloot, J Van Ingen, C Andrejak, K Ängeby, R Bauriaud, P Bemer, ... European Respiratory Journal 42 (6), 1604-1613, 2013 | 874 | 2013 |
| Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar, LF Anderson, ... The Lancet 392 (10150), 821-834, 2018 | 533 | 2018 |
| Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands A Tostmann, SV Kik, NA Kalisvaart, MM Sebek, S Verver, MJ Boeree, ... Clinical Infectious Diseases 47 (9), 1135-1142, 2008 | 413 | 2008 |
| High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial MJ Boeree, N Heinrich, R Aarnoutse, AH Diacon, R Dawson, S Rehal, ... The Lancet infectious diseases 17 (1), 39-49, 2017 | 383 | 2017 |
| A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis MJ Boeree, AH Diacon, R Dawson, K Narunsky, J Du Bois, A Venter, ... American journal of respiratory and critical care medicine 191 (9), 1058-1065, 2015 | 359 | 2015 |
| Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria J van Ingen, MJ Boeree, D van Soolingen, JW Mouton Drug Resistance Updates 15 (3), 149-161, 2012 | 351 | 2012 |
| New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development J van den Boogaard, GS Kibiki, ER Kisanga, MJ Boeree, RE Aarnoutse Antimicrobial agents and chemotherapy 53 (3), 849-862, 2009 | 342 | 2009 |
| Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence MA Gordon, HT Banda, M Gondwe, SB Gordon, MJ Boeree, AL Walsh, ... Aids 16 (12), 1633-1641, 2002 | 337 | 2002 |
| Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies J van Ingen, Z Rahim, A Mulder, MJ Boeree, R Simeone, R Brosch, ... Emerging infectious diseases 18 (4), 653, 2012 | 325 | 2012 |
| Nontuberculous mycobacteria in respiratory tract infections, eastern Asia S Simons, J Van Ingen, PR Hsueh, N Van Hung, PNR Dekhuijzen, ... Emerging infectious diseases 17 (3), 343, 2011 | 310 | 2011 |
| Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands J van Ingen, SA Bendien, WCM de Lange, W Hoefsloot, PNR Dekhuijzen, ... Thorax 64 (6), 502-506, 2009 | 306 | 2009 |
| Why do we use 600 mg of rifampicin in tuberculosis treatment? J Van Ingen, RE Aarnoutse, PR Donald, AH Diacon, R Dawson, ... Clinical Infectious Diseases 52 (9), e194-e199, 2011 | 304 | 2011 |
| Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study JM Bryant, SR Harris, J Parkhill, R Dawson, AH Diacon, P van Helden, ... The Lancet Respiratory Medicine 1 (10), 786-792, 2013 | 232 | 2013 |
| Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers CJL La Porte, EPH Colbers, R Bertz, DS Voncken, K Wikstrom, MJ Boeree, ... Antimicrobial agents and chemotherapy 48 (5), 1553-1560, 2004 | 227 | 2004 |
| MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network GB Migliori, S Tiberi, A Zumla, E Petersen, JM Chakaya, C Wejse, ... International Journal of Infectious Diseases 92, S15-S25, 2020 | 226 | 2020 |
| Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment SO Friedrich, A Rachow, E Saathoff, K Singh, CD Mangu, R Dawson, ... The lancet Respiratory medicine 1 (6), 462-470, 2013 | 213 | 2013 |
| The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment J van Ingen, EF Egelund, A Levin, SE Totten, MJ Boeree, JW Mouton, ... American journal of respiratory and critical care medicine 186 (6), 559-565, 2012 | 201 | 2012 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report S Borisov, E Danila, A Maryandyshev, M Dalcolmo, S Miliauskas, L Kuksa, ... European Respiratory Journal 54 (6), 2019 | 191 | 2019 |
| Care seeking behaviour and diagnostic processes in patients with smear-positive pulmonary tuberculosis in Malawi FML Salaniponi, AD Harries, HT Banda, C Kang'ombe, N Mphasa, ... The International Journal of Tuberculosis and Lung Disease 4 (4), 327-332, 2000 | 171 | 2000 |
